GlaxoSmithKline asthma drug receives positive EU opinion

GlaxoSmithKline said the European Medicines Agency (EMA) had given a positive opinion on its Nucala drug to be self-administered to treat severe asthma.

The EMA's human medicines committee (CHMP) cleared the drug mepolizumab, branded as Nucala, and recommended two new methods for administering the drug to patients with severe eosinophils asthma.

If approved, the two new Nucala options would offer healthcare professionals the choice of prescribing at-home administration for appropriate patients, Glaxo said in a statement.

A CHMP positive opinion is one of the final steps before marketing authorisation is granted by the European Commission, it added.